Synthesis and anticancer activity of N-9- and N-7- substituted 1,2,3 triazole analogues of 2,6-di-substituted purine

  • Jabeena KhazirEmail author
  • Bilal Ahmad Mir
  • Gousia Chashoo
  • Lynne Pilcher
  • Darren Riley
Original Research


A library of N-9- and N-7-substituted 1,2,3 triazole analogues were generated on the 2,6-di-substituted purine upon reaction with various substituted aromatic azides. The synthesised analogues were screened for in vitro cytotoxic activity against various human cancer cell lines like (HCT-1 (colon), THP-1 (leukaemia), IMR-32 (neuroblastoma) and A-549 (lung)). From the bioassay results, it was observed that even though most of the synthesized derivatives exhibited a good potency against various screened cancer cell lines, but few of the analogues like 9a, 9b and 9e were found to be the most potent analogues in the series, with compound 9a showing IC50 values of 0.08 and 0.4 μM against THP-1 and A-549 cell lines, respectively.


2,6 Dichloropurine Cycloaddition 1,2,3 triazoles anticancer 



Phenyl ring


Benzyl amine


Triazole ring


Purine ring


Ethanol amine






Methylene group attached to benzene ring of benzyl amine


Methylene group attached to Triazole ring



We thank University of Pretoria for providing postdoctoral fellowship to JK.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Supplementary material

44_2019_2456_MOESM1_ESM.pdf (1.2 mb)
Supplementary Information


  1. De Clercq E (1997) Current and potential therapies for the treatment of herpes-virus infections. Clin Microbiol Rev 10:674–669CrossRefPubMedPubMedCentralGoogle Scholar
  2. Hansen SW, Skovsgaard T, Sorensen JB (1985) Treatment of small cell lung cancer with 6-mercaptopurine: A phase II study. Cancer Treat Rep 69:555PubMedGoogle Scholar
  3. Havlicek L, Hanus J, Vesely J, LeClerc S, Meijer L, Shaw G, Strnad M (1997) 8-Azapurines as new inhibitors of cyclin-dependent kinases. J Med Chem 40:408–412CrossRefPubMedGoogle Scholar
  4. Jeannette CA, Christian EP, Álvaro CM, Ricardo AT, Mario F, Maria JT, Adam A, Margot P, Cristian OS (2015) Synthesis and pharmacophore modelling of 2,6,9-trisubstituted purine derivatives and their potential role as apoptosis-inducing agents in cancer cell lines. Molecules 20(4):6808–6826CrossRefGoogle Scholar
  5. Kay NE (1981) Abnormal T cell subpopulation function in CLL: excessive suppressor and deficient helper activity with respect to B cell proliferation. Blood 57:418–420CrossRefPubMedGoogle Scholar
  6. Legraverend M, Grierson DS (2006) The purines: potent and versatile small molecule inhibitors and modulators of key biological targets. Med Chem 14:3987–4006CrossRefGoogle Scholar
  7. MacCallum DE, Melville J, Frame S, Watt K, Anderson S, Gianella-Borradori A, Lane DP, Green SR (2005) Seliciclib (CYC202, R-Roscovitine) induces cell death in multiple myeloma cells by inhibition of RNA polymerase II-dependent transcription and down-regulation of Mcl-1. Cancer Res 65:5399–5407CrossRefGoogle Scholar
  8. Marr JJ (1991) Purine analogs as chemotherapeutic agents in leishmaniasis and American trypanosomiasis. J Lab Clin Med 118:111–119PubMedGoogle Scholar
  9. Mary EL, Patrick EC, Satya N, Brian KL (2015) Cyclin-dependent kinase inhibitors as anticancer therapeutics. Mol Pharmacol 88:846–852CrossRefGoogle Scholar
  10. Masson C (1983) Treatment of herpes with acyclovir. Presse Med 12:1399–1400PubMedGoogle Scholar
  11. McClue SJ, Blake D, Clarke R, Cowan A, Cummings L, Fischer PM, MacKenzie M, Melville J, Stewart K, Wang S, Zhelev N, Zheleva D, Lane DP (2002) Int J Cancer 102:463–468CrossRefPubMedGoogle Scholar
  12. Melroy J, Nair V (2005) The antiviral activity, mechanism of action, clinical significance and resistance of abacavir in the treatment of pediatric AIDS. Curr Pharm Des 11:3847–3852CrossRefPubMedGoogle Scholar
  13. Munshi PN, Lubin M, Bertino JR (2014) 6-Thioguanine: a drug with unrealized potential for cancer therapy. Oncologist 19:760–765CrossRefPubMedPubMedCentralGoogle Scholar
  14. Nabhan C, Gartenhaus RB, Tallman MS (2004) Purine nucleoside analogues and combination therapies in B-cell chronic lymphocytic leukaemia: dawn of a new era. Leuk Res 28(5):429–442CrossRefPubMedGoogle Scholar
  15. Panos F, Bruce CA, Michael LG (1996) Purine analogs for the treatment of low-grade lymph proliferative disorder. Oncologist 1(3):125–139Google Scholar
  16. Perez OD, Chang YT, Rosania G, Sutherlin D, Schultz PG (2002) Inhibition and reversal of myogenic differentiation by purine-based microtubule assembly inhibitors. Chem Biol 9(4):475–483CrossRefPubMedGoogle Scholar
  17. Quan DJ, Peters MG (2004) Antiviral therapy: nucleotide and nucleoside analogs. Clin Liver Dis 8(2):371–385CrossRefPubMedGoogle Scholar
  18. Rosemeyer H (2004) The chemo diversity of purine as a constituent of natural products. Chem Biodivers 1:361–401CrossRefGoogle Scholar
  19. Saman MV, Salim KY, Danter WR, Koropatnick J (2018) PLoS ONE 13(1):e0191766CrossRefGoogle Scholar
  20. Siegel-Lakhai WS, Rodenstein DO, Beijnen JH, Gianella-Borradori A, Schellens JHM, Talbot DC (2005) Clinical trial designs. J Clin Oncol 23:2060–2060Google Scholar
  21. Vince R (1991) Synthesis and anti-HIV activity of carbovir and related carbocyclic nucleosides. Nucl Acids Symp Ser 25:193–194Google Scholar
  22. Wang X, Wang L, Wu N, Ma X, Xu J (2015) Clinical efficacy of oral ganciclovir for prophylaxis and treatment of recurrent herpes simplex keratitis: corrigendum. Chin Med J 128:46–50CrossRefPubMedPubMedCentralGoogle Scholar
  23. WS Hsieh, R Soo, BK Peh, T Loh, D Dong, D Soh, LS Wong, S Green,J Chiao, CY Cui, YF Lai, SC Lee, B Mow, R Soong, M Salto-Tellez, BC Goh (2009) Pharmacodynamic effects of seliciclib, an orally administered cell cycle modulator, in undifferentiated nasopharyngeal cancer. Clin Cancer Res 15:1435–1442CrossRefPubMedGoogle Scholar
  24. Welsch ME, Snyder SA, Stockwell BR (2010) Privileged scaffolds for library design and drug discovery. Curr Opin Chem Biol 2010(14):347–361CrossRefGoogle Scholar
  25. Whittaker SR, Te Poele RH, Chan F, Linardopoulos S, Walton MI, Garrett MD, Workman P (2007) The cyclin-dependent kinase inhibitor seliciclib (R-roscovitine; CYC202) decreases the expression of mitotic control genes and prevents entry into mitosis. Cell Cycle 6:3114–3131CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  • Jabeena Khazir
    • 1
    Email author
  • Bilal Ahmad Mir
    • 2
  • Gousia Chashoo
    • 3
  • Lynne Pilcher
    • 4
  • Darren Riley
    • 4
  1. 1.Department of ChemistryGovernment Degree College (Boys)PulwamaIndia
  2. 2.Department of Botany, Satellite Campus KargilUniversity of KashmirSrinagarIndia
  3. 3.Cancer Pharmacology DivisionCSIR-Indian Institute of Integrative Medicine, Canal RoadJammuIndia
  4. 4.Department of ChemistryUniversity of PretoriaPretoriaSouth Africa

Personalised recommendations